You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR PRALATREXATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for pralatrexate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004238 ↗ 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
NCT00004238 ↗ 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 1999-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
NCT00024245 ↗ 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 2001-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Probenecid may increase the effectiveness of 10-propargyl-10-deazaaminopterin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining 10-propargyl-10-deazaaminopterin and probenecid in treating patients who have advanced solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for pralatrexate

Condition Name

Condition Name for pralatrexate
Intervention Trials
Peripheral T-cell Lymphoma 5
Refractory Peripheral T-Cell Lymphoma 3
Peripheral T Cell Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for pralatrexate
Intervention Trials
Lymphoma 24
Lymphoma, T-Cell 21
Lymphoma, T-Cell, Peripheral 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for pralatrexate

Trials by Country

Trials by Country for pralatrexate
Location Trials
United States 135
United Kingdom 9
France 9
Hungary 8
Italy 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for pralatrexate
Location Trials
New York 21
California 13
Texas 9
New Jersey 8
Massachusetts 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for pralatrexate

Clinical Trial Phase

Clinical Trial Phase for pralatrexate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for pralatrexate
Clinical Trial Phase Trials
Completed 25
Recruiting 6
Withdrawn 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pralatrexate

Sponsor Name

Sponsor Name for pralatrexate
Sponsor Trials
Spectrum Pharmaceuticals, Inc 16
Acrotech Biopharma LLC 10
National Cancer Institute (NCI) 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for pralatrexate
Sponsor Trials
Industry 41
Other 39
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.